Knockout of immunotherapy prognostic marker genes eliminates the effect of the anti-PD-1 treatment
Abstract The efficacy of immunotherapy is largely patient-specific due to heterogeneity in tumors. Combining statistic power from a variety of immunotherapies across cancer types, we found four biological pathways significantly correlated with patient survival following immunotherapy. The expression...
Guardado en:
Autores principales: | Naixue Yang, Fansen Ji, Liqing Cheng, Jingzhe Lu, Xiaofeng Sun, Xin Lin, Xun Lan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d1b53626f5384d8199251343281d89a5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
por: Chao Liu, et al.
Publicado: (2021) -
Correction: Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
Publicado: (2021) -
Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
por: Min Yu, et al.
Publicado: (2021) -
Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
Publicado: (2021) -
Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy
por: Sjoerd H van der Burg, et al.
Publicado: (2021)